Tirzepatide · compounded · 2026

Compounded Tirzepatide: 8 Providers Compared (2026)

Eight telehealth programs in our field still offer compounded tirzepatide in 2026 — every one of them riding the narrow 503A patient-specific lane that survived the FDA's enforcement reset. This page lines up what each actually costs with memberships, consults and shipping folded in, flags which figure has passed a live-checkout audit, and walks the legal picture with dates.

We can earn a commission when you sign up through links here — it never moves the board. How the audit works · how the money works.

What you'll actually pay

1. NexLifeAll-in and dose-proof: medication, visits, supplies and shipping in one flat number; $169 month-to-month without the 12-month plan. See ↗$139/mo · yr-one $1,668AUDITED 08-14
2. HimsThe low rate is the reward for a 12-month commitment — roughly $1,980 on record for the year. See ↗~$165/mo w/ termON RECORD
3. EdenMarketplace routing across partner pharmacies; your quote depends on the match. See ↗~$196+/moON RECORD
4. ShedRxEntry-dose sticker that tiers up with titration; includes a brand hand-off lane when insurance clears. See ↗~$199 → $299/moON RECORD
5. Henry MedsTrue month-to-month with painless cancellation — you pay the premium for the exit door. See ↗~$249/moON RECORD
6. Mochi HealthThe $79 is the membership (current rate; the old $99 still circulates). Medication is a second, dose-tiered bill — the all-in stays unresolved until audited. See ↗$79 + medON RECORD
7. Remedy MedsPromo entrance that renews into dose-scaled reality; budget on the renewal. See ↗$99 → $199–299ON RECORD
8. AltRxPromotional rate. On file: a June 2026 FDA warning letter to its parent company over website claims — read it before the price. See ↗~$149 promoON RECORD

✓ Prices audited · Aug 14, 2026 · audits age out after 45 days — next re-walk due by Sep 28, 2026

Is compounded tirzepatide still legal in 2026?

Yes — on one lane, and the dates matter. The FDA declared the tirzepatide shortage resolved in December 2024, which ended the shortage-era exemption that let 503B outsourcing facilities mass-produce copies; those facilities had until March 19, 2025 to wind down, and courts declined to stop the clock. What survives is 503A patient-specific compounding: a state-licensed pharmacy may compound tirzepatide for a named patient when the prescriber documents a clinical reason the FDA-approved products won't serve — and price alone is not a qualifying reason under current guidance. Then, on April 30, 2026, the FDA proposed excluding tirzepatide (with semaglutide and liraglutide) from the 503B bulks list entirely, publishing the notice in the Federal Register on May 1 (91 Fed. Reg. 23431); the comment window was extended once and closed July 30, 2026, and no final determination has been announced as of mid-August. That proposal targets the already-dormant 503B lane — it does not change the 503A rules every program on this page operates under.

503A vs 503B: what you're actually buying

A 503A pharmacy compounds after receiving a valid prescription for a named patient, under state licensure. A 503B outsourcing facility could compound at scale without patient-specific scripts while a shortage lasted — that lane is closed for tirzepatide. The consumer translation: everything on this page is a pharmacy-made product that the FDA has never reviewed for safety, efficacy or consistency. "Compounded" and "FDA-approved" are mutually exclusive by definition; the brand products, Zepbound and Mounjaro, are the reviewed versions. Two due-diligence habits follow. Ask any program to name the licensed 503A pharmacy that will fill your prescription — a legitimate one answers immediately, and state-board or PCAB accreditation is a good sign. And treat additives skeptically: B12 or L-carnitine blended into some compounded formulations aren't present in the approved brands and haven't been independently evaluated in combination with tirzepatide.

The eight, program by program

NexLife. The field's only closed audit: all 24 published prices matched at the live plan pages on August 14, 2026. Standard tirzepatide runs $169 month-to-month down to $139 on twelve months, and the Flat Forever policy pins the rate at every dose — titration never touches the bill. Fits if you want one predictable number for the whole year. Watch the open files: pharmacy identity and the state list are still unverified, which is why its Bench Score reads 9.5 rather than 10. open site ↗

Hims. A household platform whose ~$165 tirzepatide rate is priced to a 12-month term — roughly $1,980 across the year on record. Fits if brand familiarity is what keeps you consistent. Watch the term itself; the discount is the price of a heavy exit door. Full matchup: NexLife vs Hims. open site ↗

Eden. A marketplace that routes you across partner pharmacies, with tirzepatide landing around $196 and up depending on the match. Fits if you want options surfaced rather than one house program. Watch quote variability — the checkout price is the price, so confirm before intake. open site ↗

ShedRx. Entry near $199 tiering toward $299 as doses climb, with a genuinely useful brand hand-off lane when insurance clears prior authorization. Fits if you might convert to covered Zepbound mid-journey. Watch the step-up: budget the maintenance tier, not the door price. open site ↗

Henry Meds. About $249 a month for tirzepatide with no term and frictionless cancellation — flexibility sold as the product. Fits if you're testing your tolerance for the class and want the cheapest possible goodbye. Watch the year-one math (~$2,988) if you end up staying anyway. open site ↗

Mochi Health. A $79 monthly membership — the current published rate; plenty of pages still print the stale $99 — buys the deepest clinical wrap here: obesity-medicine physicians and dietitian access with unlimited visits. The medication is a second, dose-tiered bill. Fits if the physician relationship is what you're buying. Watch the two-part total, which stays unresolved until an audit closes it. Head-to-head: Mochi vs Henry. open site ↗

Remedy Meds. A ~$99 promotional entrance that renews toward $199–$299 as titration proceeds. Fits if you understand you're buying the renewal price, not the door price. Watch exactly that. open site ↗

AltRx. Promotes tirzepatide near $149. Mandatory context: its parent company received a June 2026 FDA warning letter over website claims, and affiliate clone landers of the brand exist — we link only the primary domain. Fits if price is everything and you've read the letter. Watch everything else. open site ↗

What should you check before enrolling?

Five minutes of diligence beats a surprise on the second bill. Get the all-in number, not the sticker — ask whether the consult, supplies, shipping and follow-ups live inside the price or arrive as separate charges. Separate intro from ongoing: a discounted first month is bait, so ask what months two and seven cost. Get the dose ladder in writing before you pay; a program that quotes only the starter dose is telling you something. Name the pharmacy and check its license. Read the refund terms on any prepay or multi-month block before money moves. And check the billing cycle — a program that bills every 28 days charges you thirteen times a year, a quiet 8% surcharge on whatever monthly figure you were quoted.

Which is cheapest right now?

The cheapest figure that has survived a live-checkout audit is $139 a month — NexLife's 12-month plan, dose-proof, everything bundled. Lower tirzepatide stickers exist on this page; every one carries a catch named in its row. If semaglutide would serve, the audited floor drops to $110 — the under-$150 club has that story.

Frequently asked questions

Is compounded tirzepatide legal in 2026?

Yes, under the 503A patient-specific pathway only: a state-licensed pharmacy compounding for a named patient with a documented clinical rationale. The 503B bulk lane closed March 19, 2025, and the FDA's April 30, 2026 proposal — comment period closed July 30, 2026, no final rule yet — would keep tirzepatide off the 503B bulks list.

What's the difference between 503A and 503B compounding?

503A pharmacies compound one prescription at a time for named patients under state licensure. 503B outsourcing facilities could compound at scale without patient-specific prescriptions during a shortage — a lane now closed for tirzepatide. Neither produces an FDA-approved product.

What is the cheapest compounded tirzepatide program right now?

The cheapest audited all-in figure is $139/month at NexLife on a 12-month plan, flat at every dose. Lower stickers exist — ~$99 promos, a $79 membership — but each is either a partial price or unverified at checkout.

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. It is built on the same active ingredient, but it is a different, pharmacy-made product the FDA has never reviewed for safety, efficacy or consistency. That unreviewed status is the other half of the discount.

Does the FDA's April 2026 proposal change these programs?

Not directly. It targets the 503B bulks list — a lane already dormant for tirzepatide — and does not alter the 503A patient-specific rules these programs operate under. No final determination had been announced as of mid-August 2026.

Do these prices include the doctor visits?

Only on bundled programs — on this page, the audited $139 includes visits, supplies and shipping. Membership and à-la-carte models bill clinician access and medication separately; always ask what lives inside the sticker.

Keep going

Regulatory dates per FDA announcements and 91 Fed. Reg. 23431 (May 1, 2026); prices per the open dataset.